Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity

Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, John Meijer, Adriana Hollestein-Havelaar, Frank Verheggen, Donald Newgreen, Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, John Meijer, Adriana Hollestein-Havelaar, Frank Verheggen, Donald Newgreen

Abstract

The aim of this investigation was to characterize and compare the pharmacokinetics (PK) of the antimuscarinic drug solifenacin in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) utilizing data from three phase III trials. LION was a placebo-controlled, 12-week trial in children (5-<12 years) and adolescents (12-<18 years) with OAB. MONKEY and MARMOSET were open-label, 52-week trials in children and adolescents or younger children (6 months-<5 years), respectively, with NDO. During the trials, solifenacin doses could be titrated to weight-adjusted pediatric equivalent doses (PEDs) of 2.5, 5, 7.5, or 10 mg day-1 . Nonlinear mixed effects modeling was used to develop population PK models to characterize the PK in patients with either OAB or NDO. Overall, 194 children and adolescents received solifenacin. At the time of PK sampling, the majority (119/164 [72.6%] patients) were receiving PED10 once daily. All population models included first-order oral absorption, a lag time, and interindividual variability. PK analysis showed that apparent clearance was similar in both patient populations. Mean apparent oral plasma clearance (CL/F), apparent volume of distribution during the terminal phase (Vz /F), and terminal half-life (t1/2 ) were higher in adolescents than in children, but median time to maximum plasma concentration (tmax ) was similar. Dose-normalized exposure results were similar for both younger and older patients with OAB or NDO. In conclusion, population PK modeling was used to successfully characterize solifenacin PK in pediatric patients with OAB or NDO. Similar solifenacin PK characteristics were observed in both populations.

Trial registration: ClinicalTrials.gov NCT01565707 NCT01565694 NCT01981954.

Keywords: nephrology - urology; pediatrics - children; pharmacokinetics.

Conflict of interest statement

All the authors are current or former employees of either Astellas Pharma Europe B.V. or Astellas Pharma Global Development Inc. The authors thank the LION, MONKEY, and MARMOSET trial investigators, and all the patients and their parents/legal representatives who took part in the trials. These trials were funded by Astellas Pharma Europe B.V. Medical writing support was provided by Michael Parsons, PhD, CMPP of Elevate Scientific Solutions, who provided permission to be named in this section, and funded by Astellas Pharma Global Development, Inc. The authors also thank the contract research organization involved in conducting these trials, PPD Global Limited, Cambridge, UK.

© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

Figures

FIGURE 1
FIGURE 1
Trial designs for the LION (OAB population; (A), MONKEY (NDO population; (B), and MARMOSET (NDO population; (C) trials. NDO, neurogenic detrusor overactivity; OAB, overactive bladder; PED, pediatric equivalent dose. Figure 1A reprinted from Eur Urol, 71, Newgreen D, Bosman B, Hollestein‐Havelaar A, Dahler E, Besuyen R, Sawyer W, et al. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial, 483‐90, Copyright (2017), with permission from Elsevier. 26 Figure 1B and Cadapted from Franco, et al. 30 aEvery 3 weeks, dose modification of trial drug could be performed to obtain doses of PED2.5, PED5, PED7.5, or PED10. bWeight‐adjusted starting dose was equivalent to 5 mg in adults. cThe fixed‐dose assessment period started when the optimal dose for the patient was reached and it ended at week 52. dWeight‐adjusted starting dose was equivalent to 2.5 or 5 mg in adults depending on patient age
FIGURE 2
FIGURE 2
Dose‐normalized concentration‐time profiles for the patients enrolled in the LION (OAB population), MONKEY (NDO population), and MARMOSET (NDO population) trials. NDO, neurogenic detrusor overactivity; OAB, overactive bladder; SD, standard deviation. Data shown are geometric means ± SD. The curves are calculated using the nominal times for the concentration samples
FIGURE 3
FIGURE 3
Dose‐normalized exposures according to age group for the patients enrolled in the LION (OAB population; (A), MONKEY (NDO population; (B), and MARMOSET (NDO population; (C) trials. AUC, area under the plasma concentration‐time curve; AUC/D, dose‐normalized area under the plasma concentration‐time curve; Cmax, maximum plasma concentration; Cmax/D, dose‐normalized maximum plasma concentration; NDO, neurogenic detrusor overactivity; OAB, overactive bladder. The circles represent the individual values for each patient. The line within each plot represents the geometric mean

References

    1. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn. 2016;35:471‐481.
    1. Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI‐RS 2013. Neurourol Urodyn. 2014;33:622‐624.
    1. Chung JM, Lee SD, Kang DI, et al. Prevalence and associated factors of overactive bladder in Korean children 5–13 years old: a nationwide multicenter study. Urology. 2009;73:63‐67.
    1. Hellström A, Hanson E, Hansson S, Hjälmås K, Jodal U. Micturition habits and incontinence at age 17 – reinvestigation of a cohort studied at age 7. Br J Urol. 1995;76:231‐234.
    1. Kajiwara M, Inoue K, Mutaguchi K, Usui T. The prevalence of overactive bladder and nocturnal enuresis in Japanese early adolescents : a questionnaire survey. Hinyokika Kiyo. 2006;52:107‐111.
    1. Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study. Int J Urol. 2006;13:36‐41.
    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub‐committee of the International Continence Society. Neurourol Urodyn. 2002;21:167‐178.
    1. Verpoorten C, Buyse GM. The neurogenic bladder: medical treatment. Pediatr Nephrol. 2008;23:717‐725.
    1. Kennelly MJ, DeVoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008;10:182‐191.
    1. Burkhard FC, Bosch JLHR, Cruz F, et al. EAU urinary incontinence guidelines 2018. Available at (last accessed 16 June 2020).
    1. Rawashdeh YF, Austin P, Siggaard C, et al. International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012;31:615‐620.
    1. Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assoc J. 2017;11:S74‐S79.
    1. Oxybutynin hydrochloride 5mg tablets: Summary of Product Characteristics (04 January 2018) . Available at (last accessed 16 June 2020).
    1. Regurin 20 mg coated tablets: Summary of Product Characteristics (25 June 2019) . Available at (last accessed 16 June 2020).
    1. Cardozo L, Amarenco G, Pushkar D, et al. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double‐blind trial of solifenacin (SUNRISE). BJU Int. 2013;111:804‐810.
    1. Chapple CR, Martinez‐Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464‐470.
    1. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero‐Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double‐blind, placebo‐controlled trial. Urology. 2009;73:14‐18.
    1. Krebs J, Pannek J. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion. Spinal Cord. 2013;51:306‐309.
    1. Amarenco G, Sutory M, Zachoval R, et al. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double‐blind, randomized, active‐ and placebo‐controlled SONIC urodynamic study. Neurourol Urodyn. 2017;36:414‐421.
    1. Fang G. Solifenacin oral suspension NDA (03 August 2017). Available at (last accessed 16 June 2020).
    1. Astellas . News release. Astellas obtained approval for Vesicare OD in Japan. Available at (last accessed 16 June 2020).
    1. Vesicare 10mg film‐coated tablets: Summary of Product Characteristics (13 November 2019) . Available at (last accessed 16 June 2020).
    1. Vesicare oral suspension: Summary of Product Characteristics (12 November 2019) . Available at (last accessed 16 June 2020).
    1. Lee SD, Chung JM, Kang DI, Ryu DS, Cho WY, Park S. Efficacy and tolerability of solifenacin 5 mg fixed dose in Korean children with newly diagnosed idiopathic overactive bladder: a multicenter prospective study. J Korean Med Sci. 2017;32:329‐334.
    1. Hoebeke P, De Pooter J, De Caestecker K, et al. Solifenacin for therapy resistant overactive bladder. J Urol. 2009;182:2040‐2044.
    1. Newgreen D, Bosman B, Hollestein‐Havelaar A, et al. Solifenacin in children and adolescents with overactive bladder: results of a phase 3 randomised clinical trial. Eur Urol. 2017;71:483‐490.
    1. Newgreen D, Bosman B, Hollestein‐Havelaar A, et al. Long‐term safety and efficacy of solifenacin in children and adolescents with overactive bladder. J Urol. 2017;198:928‐936.
    1. Bosman B, Tannenbaum S, Winklewski P, den Adel M, Newgreen D, Baka‐Ostrowska M. A multicenter, open‐label, single‐dose study to evaluate the pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric subjects from 5 to less than 18 years of age with neurogenic detrusor overactivity (NDO). Presented at ICS 2013, 26–30 August 2013, Barcelona, Spain. Available at (last accessed 16 June 2020).
    1. Nadeau G, Schröder A, Moore K, et al. Long‐term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open‐label study. Can Urol Assoc J. 2014;8:118‐123.
    1. Franco I, Hoebeke P, Baka‐Ostrowska M, et al. Long‐term efficacy and safety of solifenacin in pediatric patients aged 6 months to 18 years with neurogenic detrusor overactivity: results from two phase 3 prospective open‐label studies. J Pediatr Urol. 2020;16:180.e1‐180.e8.
    1. Astellas received approval for solifenacin oral suspension for pediatric patients in Europe . Available at (last accessed 16 June 2020).
    1. FDA approves VESIcare LS™ (solifenacin succinate) oral suspension for pediatric patients . Available at (last accessed 16 June 2020).
    1. Smulders RA, Krauwinkel WJ, Swart PJ, Huang M. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004;44:1023‐1033.
    1. Kuipers ME, Krauwinkel WJJ, Mulder H, Visser N. Solifenacin demonstrates high absolute bioavailability in healthy men. Drugs R D. 2004;5:73‐81.
    1. Uchida T, Krauwinkel WJ, Mulder H, Smulders RA. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol. 2004;58:4‐7.
    1. Vesicare 5mg film‐coated tablets: Summary of Product Characteristics (13 November 2019). Available at (last accessed 16 June 2020).
    1. Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53‐72.
    1. Bosman B, Strougo A, Van der Putten‐Slob I, Vande Walle J, Hoebeke P. A multicenter, open‐label, single ascending dose study to evaluate pharmacokinetics, safety and tolerability of solifenacin succinate suspension in pediatric patients aged 5 to 17 years (inclusive) with overactive bladder. Presented at the ICCS, ERIC, BAPU Congress 2012, 12‐14 October 2012, London, UK. 2012.
    1. Nevéus T, von Gontard A, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol. 2006;176:314‐324.
    1. Lin W, Heimbach T, Jain JP, et al. A physiologically based pharmacokinetic model to describe artemether pharmacokinetics in adult and pediatric patients. J Pharm Sci. 2016;105:3205‐3213.
    1. De Cock RFW, Piana C, Krekels EHJ, Danhof M, Allegaert K, Knibbe CAJ. The role of population PK‐PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67(Suppl 1):S5‐S16.
    1. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051‐1065.
    1. Holford N. Pharmacokinetic variability due to environmental differences. Transl Clin Pharmacol. 2017;25:59‐62.
    1. Smulders RA, Smith NN, Krauwinkel WJ, Hoon TJ. Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency. J Pharmacol Sci. 2007;103:67‐74.
    1. Fox JA, Dudley AG, Bates C, Cannon GM. Cystatin C as a marker of early renal insufficiency in children with congenital neuropathic bladder. J Urol. 2014;191:1602‐1607.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren